Discontinuation report HOLKIRA PAK
| Report ID | 31302 |
| Drug Identification Number | 02436027 |
| Brand name | HOLKIRA PAK |
| Common or Proper name | HOLKIRA PAK 12.5/75/50/250MG TABS, 28DAY |
| Company Name | ABBVIE CORPORATION |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RITONAVIR Ombitasvir Dasabuvir Paritaprevir |
| Strength(s) | 50MG 12.5MG 250MG 75MG |
| Dosage form(s) | KIT TABLET |
| Route of administration | ORAL |
| Packaging size | 4 inner cartons x 7blisters |
| ATC code | J05AX |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2018-08-15 |
| Actual discontinuation date | 2018-08-15 |
| Remaining supply date | 2018-08-15 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Per AbbVie’s return policy, for your entire remaining inventory, we ask that you return product only at expiry. |
| Company comments | This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2018-08-30 | French | Compare |
| v3 | 2018-08-30 | English | Compare |
| v2 | 2017-11-30 | French | Compare |
| v1 | 2017-11-30 | English | Compare |
Showing 1 to 4 of 4